US 12,252,495 B2
Protein kinase B inhibitors
Paul David Johnson, Macclesfield (GB); Andrew Leach, Macclesfield (GB); Richard William Arthur Luke, Macclesfield (GB); Zbigniew Stanley Matusiak, Macclesfield (GB); and Jeffrey James Morris, Macclesfield (GB)
Assigned to ASTRAZENECA AB, Södertälje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Aug. 4, 2023, as Appl. No. 18/365,286.
Application 18/365,286 is a continuation of application No. 17/644,654, filed on Dec. 16, 2021, granted, now 11,760,760.
Application 17/644,654 is a continuation of application No. 16/841,820, filed on Apr. 7, 2020, granted, now 11,236,095, issued on Feb. 1, 2022.
Application 16/841,820 is a continuation of application No. 16/028,979, filed on Jul. 6, 2018, granted, now 10,654,855, issued on May 19, 2020.
Application 16/028,979 is a continuation of application No. 15/351,481, filed on Nov. 15, 2016, granted, now 10,059,714, issued on Aug. 28, 2018.
Application 15/351,481 is a continuation of application No. 14/626,303, filed on Feb. 19, 2015, granted, now 9,492,453, issued on Nov. 15, 2016.
Application 14/626,303 is a continuation of application No. 13/324,191, filed on Dec. 13, 2011, abandoned.
Application 13/324,191 is a continuation of application No. 12/249,477, filed on Oct. 10, 2008, granted, now 8,101,623, issued on Jan. 24, 2012.
Claims priority of provisional application 61/047,862, filed on Apr. 25, 2008.
Claims priority of provisional application 60/979,192, filed on Oct. 11, 2007.
Prior Publication US 2024/0109902 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 473/34 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61P 35/04 (2018.01); C07D 473/34 (2013.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A method of treating luminal breast cancer, comprising:
administering to a person in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
Y represents N;
Z1-Z2 represents C(R6)═CH; where
R6 represents hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, difluoromethyl, trifluoromethyl or cyclopropyl;
n is 0, 1 or 2;
R1 represents C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl, fluoroC1-4alkyl, aminoC1-4alkyl, hydroxyC1-4alkyl, cyano, cyanoC1-4alkyl, C3-6cycloalkyl, —(CH2)pNHCOCH3, —(CH2)pNHSO2CH3, —(CH2)pNHCONH2, —(CH2)pNHCONR2R3, —(CH2)pNR2R3, —(CH2)pSO2NH2, —(CH2)pSO2NR2R3, —(CH2)pCONH2, —(CH2)pCONR2R3 or —(CH2)p—R7; where
p is 0, 1, 2 or 3;
R2 represents hydrogen or C1-3alkyl;
R3 represents C1-3alkyl; and
R7 represents phenyl;
R7 represents a 5 or 6 membered monocyclic heteroaryl ring which comprises 1, 2 or 3 heteroatoms selected from O, N or S; or
R7 represents a monocyclic 4, 5, or 6 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms selected from O, N or S;
wherein R7 is optionally substituted by 1 or 2 substituents selected from C1-4alkyl, trifluoromethyl, C1-4alkoxy, fluoro, chloro, bromo, and cyano;
R4 represents hydrogen, fluoro, chloro, bromo, cyano or trifluoromethyl; and
R5 represents hydrogen, fluoro, chloro or bromo.